Table of Contents

The CDC reports that more than 38 million Americans live with diabetes, while over 40% of adults are affected by obesity. Even with lifestyle changes and older medications, many struggle to keep A1C levels within range or to manage weight effectively.

This has led to growing interest in newer therapies like Mounjaro, a medication that targets both glucose control and body weight. But as with any new drug, the question patients keep asking is whether it’s truly safe.

This article looks closely at Mounjaro’s safety using data from clinical trials, patient reports, and medical advice. You will see what researchers have found, which side effects appear most often, and the precautions doctors consider before prescribing it.

Key Takeaways

  • Nausea, diarrhea, constipation, and vomiting are the most common side effects of Mounjaro, especially during dose increases, but they typically improve over time with gradual adjustments.
  • Although uncommon, pancreatitis, gallbladder problems, kidney injury, and worsening of eye disease have all been reported, requiring close medical monitoring.
  • The boxed warning about C-cell tumors comes from rodent studies, and while this hasn’t been proven in humans, it restricts use in those with a family or personal history of certain thyroid cancers.
  • While Mounjaro rarely causes low blood sugar on its own, the risk rises when paired with insulin or sulfonylureas, so dose adjustments are often necessary.
  • The lack of sufficient research on pregnancy and breastfeeding, along with potential impacts on birth control effectiveness, means family planning must be considered before and during treatment.

How does Mounjaro work?

Mounjaro, which contains tirzepatide, works in several ways to help manage type 2 diabetes. It lowers blood sugar by:

    • Increasing insulin only when glucose levels are elevated
    • Slows the emptying of food from the stomach
    • Decreases the release of glucagon, a hormone that raises blood sugar

In clinical trials, tirzepatide reduced A1C levels more effectively than semaglutide 1 mg and outperformed basal insulin in head-to-head studies. Participants also experienced meaningful weight loss. The most common side effects were digestive issues, usually mild to moderate and most noticeable when the dose was being increased.

Is Mounjaro safe?

Yes, most adults can take Mounjaro without serious problems, especially if the dose is increased gradually. The most common day-to-day issues involve the stomach and bowels, and these usually get better with time.

Still, there are several warnings that deserve close attention.

The medication carries a boxed warning about thyroid C-cell tumors, which were seen in rodent studies. Doctors also watch for pancreatitis, gallbladder disease, worsening diabetic eye problems in those with a prior history, and kidney injury that may occur if dehydration sets in.

Because Mounjaro delays stomach emptying, people scheduled for surgery or anesthesia may need special precautions.

If you are taking insulin or other diabetes medicines, your clinician may need to lower those doses to reduce the risk of low blood sugar. Mounjaro should not be used during pregnancy or when planning to become pregnant.

In addition, if you use oral birth control, the label advises using a backup method during each four-week dose increase.

What should you watch out for while taking Mounjaro?

Doctor showcasing a model pancreas on his desk

Below are a few safety concerns you should keep in mind.

1. Thyroid warning

Animal studies found that GLP-1 medications like tirzepatide caused thyroid C-cell tumors in rodents. It is not known whether this happens in people. Because of this, Mounjaro should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

The FDA label also advises counseling patients on warning signs such as:

    • a neck lump
    • persistent hoarseness
    • difficulty swallowing
    • trouble breathing

If you or a relative has MTC or MEN2, you should not use tirzepatide or Mounjaro. If you develop new neck changes or ongoing throat symptoms, stop the medication and contact your clinician immediately.

2. Pancreatitis

A large study in 2023 found that tirzepatide did not significantly raise the risk of pancreatitis compared with other treatments or placebo. Even so, isolated cases of acute pancreatitis have been documented in people taking the drug.

One such case involved a 32-year-old woman who, after five weeks on Mounjaro for weight loss, developed severe upper abdominal pain along with nausea and vomiting.

Tests showed high pancreatic enzymes, and imaging confirmed acute pancreatitis with small gallstones, though there was no active gallbladder infection. Her doctors believed tirzepatide likely contributed, especially since her pain eased after she missed her next dose.

She was treated with pain relief, IV fluids, and careful nutrition support in the hospital. Her condition improved, and she was advised to stop tirzepatide.

Another case involved a 64-year-old woman with no major risk factors who developed fulminant, necrotizing pancreatitis shortly after starting tirzepatide. Sadly, she did not survive.

If you’ve ever had pancreatitis, let your doctor know before starting Mounjaro. If you develop sudden, severe abdominal pain, often radiating to the back, and vomiting, stop the injections and seek care right away.

3. Gallbladder and biliary disease

A study found that people taking tirzepatide were almost twice as likely to experience gallbladder or bile duct issues compared to placebo or basal insulin. However, when looking at specific conditions like gallstones (cholelithiasis), gallbladder inflammation (cholecystitis), or bile duct disease separately, the increased risk wasn’t significant.

Report any new right-sided abdominal pain, fever, jaundice, or pale stools to your clinician. They may order an ultrasound to check for gallstones.

4. Stomach, bowel, and anesthesia concerns

Because tirzepatide slows stomach emptying, many people feel fuller quickly and have less appetite. This also explains the common digestive side effects. In trials, nausea occurred in 12-18%, diarrhea in 12-17%, vomiting in 5-9%, and constipation in 6-7%.

Most symptoms were mild to moderate, happened during dose increases, and improved over time. A small number of people stopped treatment because of these issues.

There is also an anesthesia warning. Rare cases of pulmonary aspiration, where stomach contents enter the lungs, have been reported in people on GLP-1 drugs during surgery. Before any procedure, inform your surgeon and anesthesiologist so they can plan safely.

5. Kidney safety

Dehydration from vomiting or diarrhea can cause sudden kidney injury, and in some cases, require dialysis. At the same time, studies suggest tirzepatide may help kidney health long-term by improving glucose control and lowering albuminuria. Both effects can be true.

Drink enough fluids, especially if you have stomach upset. Call your doctor if you can’t keep fluids down, and ask if you should have kidney tests after severe vomiting or diarrhea.

6. Eye safety

Fast drops in blood sugar can sometimes worsen diabetic retinopathy in the short term. For this reason, the tirzepatide label advises careful monitoring if you have existing eye disease.

Recent studies also suggest possible links between GLP-1 use and conditions such as age-related macular degeneration, though findings are mixed and more research is needed.

Researchers in Ontario, Canada, looked at health records of more than 1.1 million people with diabetes, age 66 and older. Everyone was followed for up to 3 years to see who developed neovascular age-related macular degeneration (nAMD), the more severe “wet” form of AMD that can cause vision loss.

The risk of nAMD was about twice as high in patients taking GLP-1 medicines compared with those who weren’t. However, the actual number of cases was still small, 0.2% of GLP-1 users versus 0.1% of non-users.

In another study, there was about a 7% higher chance of developing new diabetic retinopathy in patients starting GLP-1s, but at the same time, a 20-25% lower chance of progressing to the most severe, sight-threatening complications.

Schedule a retinal exam if you have diabetes and have not had one in the past year. If you already have retinopathy, tell your eye specialist when you start tirzepatide so they can set a follow-up schedule. Report new floaters, flashes, vision blur, or dark spots right away.

7. Low blood sugar and drug combinations

On its own, Mounjaro rarely causes low blood sugar because it only triggers insulin when glucose is high. The risk increases when combined with insulin or sulfonylureas.

Work with your doctor on adjusting insulin or sulfonylurea doses before starting Mounjaro. Carry fast-acting carbohydrates and know the signs of low blood sugar, such as sweating, shaking, or confusion.

8. Pregnancy, breastfeeding, and family planning

There isn’t enough research yet to know whether tirzepatide is safe to use during pregnancy. In animal studies, the medicine caused harm to developing babies, so doctors recommend avoiding it unless the benefits clearly outweigh the risks.

It’s also not known if tirzepatide is safe while breastfeeding, since studies in nursing mothers haven’t been done.

Another concern is that tirzepatide can affect how oral birth control pills are absorbed during dose increases, which may make them less reliable. For this reason, people who want to become pregnant are usually advised to stop tirzepatide well before trying to conceive.

If you are planning to get pregnant, have a conversation with your doctor about the safest time to stop the medication.

How safe is Mounjaro compared with other GLP-1 medicines?

Different GLP-1 medications such as Ozempic, Mounjaro, Zepbound and Wegovy

In diabetes studies, tirzepatide lowered both A1C and body weight more than semaglutide at the 1 mg dose. Higher doses of tirzepatide were linked to more stomach and digestive side effects, but these were generally manageable. Serious side effects occurred at rates similar to other medicines in the same class and were usually not caused by the drug itself.

In obesity trials, tirzepatide also led to greater weight loss than semaglutide 2.4 mg, with a similar pattern of gastrointestinal issues. Overall, its safety profile is in line with other incretin-based treatments.

Doctors typically decide between these medicines by looking at each person’s needs, such as how much blood sugar lowering or weight loss is required, whether there’s a history of eye or gallbladder problems, and what insurance or coverage options are available.

Practical steps that make Mounjaro treatment safer

A few mindful habits can go a long way in keeping Mounjaro therapy safe and effective.

  • Start low, go slow – Treatment usually begins at 2.5 mg once a week for the first four weeks. After that, the dose is increased gradually in 2.5 mg steps, waiting at least four weeks between changes. This slow approach helps reduce stomach problems.
  • Support your body during dose changes – Each time the dose increases, focus on hydration and protein. Small meals with lean protein and fiber are easier to handle. Fizzy drinks and heavy, fatty meals can make nausea worse. If stomach symptoms don’t improve, wait before raising the dose again.
  • Tell your surgical team – Tirzepatide can raise the risk of aspiration during anesthesia. Always share your medication list with surgeons and anesthesiologists so they can plan safely before any procedure.
  • Protect your kidneys when unwell – Vomiting or diarrhea can lead to dehydration, which stresses the kidneys. Sip oral rehydration solutions if you can. If you can’t keep fluids down, call your doctor. Ask whether you should pause other kidney-stressing medicines and if you need blood tests after severe illness.
  • Pay attention to gallbladder warning signs – Pain in the upper right side of the belly, fever, or yellowing of the skin or eyes could signal gallstones or gallbladder problems. Rapid weight loss can make these more likely, so report symptoms promptly.
  • Schedule eye checks if you have diabetes – When blood sugar improves quickly, eye disease can sometimes worsen in the short term. The American Diabetes Association (ADA) recommends an eye exam when starting stronger glucose-lowering therapy. If you already have retinopathy, closer follow-up is important.
  • Adjust other diabetes medicines – Tirzepatide by itself rarely causes low blood sugar, but combining it with insulin or sulfonylureas increases that risk. Your doctor may lower those doses when you start.
  • Stick with the real product – The FDA warns against compounded or counterfeit GLP-1 products. Always use approved Mounjaro pens from licensed and reliable sources.

Final Thoughts

Mounjaro’s safety record looks similar to other modern incretin-based medicines. The most common side effects affect the stomach and bowels, and these usually improve with time and slow dose increases.

But there are important safety warnings to keep in mind. These include the boxed thyroid cancer warning, the risk of pancreatitis, gallbladder problems, eye checks for those with diabetic retinopathy, kidney injury from dehydration, and precautions with anesthesia because of delayed stomach emptying.

Large clinical trials and regulatory agencies are continuing to track long-term safety. When used with careful monitoring, Mounjaro can be a safe option for many adults who qualify. The best approach is to work closely with your healthcare provider to build a plan that matches your health history and personal goals.

Related Articles

Frequently Asked Questions

Mounjaro is FDA-approved for type 2 diabetes management. Clinical trials, including the SURPASS program, showed significant A1C reductions and weight loss benefits in adults with diabetes.

Long-term data are still being collected, but the most monitored concerns include gastrointestinal issues, potential risk of pancreatitis, gallbladder problems, and worsening of diabetic retinopathy in those with existing disease. Rodent studies raised thyroid tumor risks, but this has not been confirmed in humans. Cardiovascular outcome trials so far suggest Mounjaro is not associated with excess heart risks and may even offer protective effects.

No, Mounjaro is only FDA-approved for type 2 diabetes. Zepbound is the same active ingredient and is approved for chronic weight management.

Mounjaro acts as a dual GIP and GLP-1 receptor agonist. It improves glucose control by enhancing insulin release, reducing glucagon, and slowing food movement through the stomach. This combination leads to lower blood sugar, improved insulin sensitivity, and often reduced appetite and body weight.

The most common side effects are nausea, vomiting, diarrhea, and constipation, usually occurring during dose escalation. Some people experience decreased appetite, fatigue, or mild abdominal discomfort. Rare but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and possible thyroid tumors, based on preclinical data.

Mounjaro requires a prescription and can be obtained from local pharmacies or mail-order services once prescribed by a licensed clinician. Availability may be limited in some areas due to high demand. Some patients also explore options through manufacturer savings programs or international pharmacies, though regulations differ.

Sources

Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519

Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1214334

Sumaruth, Y., Gopal, R., Chater, F., Dhawan, S., & Wild, T. (2025). A probable case of Tirzepatide-Induced acute pancreatitis. Cureus. https://doi.org/10.7759/cureus.85291

Grennan, K., Borg, C., Meneley, A., Janitz, T., Shuman, M., & Venegas, C. (2025). Fatal, fulminant, necrotizing pancreatitis associated with recent tirzepatide initiation. JCEM Case Reports, 3(6). https://doi.org/10.1210/jcemcr/luaf087

Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2022). Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal, 16(5), 797–808. https://doi.org/10.1093/ckj/sfac274

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022). Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology, 10(11), 774–785. https://doi.org/10.1016/s2213-8587(22)00243-1

Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025). Glucagon-Like peptide-1 receptor agonists and risk of neovascular Age-Related macular degeneration. JAMA Ophthalmology, 143(7), 587. https://doi.org/10.1001/jamaophthalmol.2025.1455

Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., Khadke, S., Kumar, A., Patel, T., Kosiborod, M. N., Fonarow, G. C., Ramsey, K. M., Nohria, A., Butler, J., & Ganatra, S. (2025). GLP-1 receptor agonists and Sight-Threatening ophthalmic complications in patients with Type 2 diabetes. JAMA Network Open, 8(8), e2526321. https://doi.org/10.1001/jamanetworkopen.2025.26321

Aronne, L. J., Horn, D. B., Roux, C. W. L., Ho, W., Falcon, B. L., Valderas, E. G., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2416394

ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Frykberg, R. G., Garg, R., Garg, S. J., Giurini, J. M., Khunti, K., Lal, R., Lingvay, I., Matfin, G., Pandya, N., . . . Bannuru, R. R. (2024). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1), S252–S265. https://doi.org/10.2337/dc25-s012